Format

Send to

Choose Destination
Mol Cancer Ther. 2012 Mar;11(3):538-48. doi: 10.1158/1535-7163.MCT-11-0555. Epub 2012 Feb 21.

The ubiquitin-proteasome system meets angiogenesis.

Author information

1
Department of Pathology, Boston University Medical Campus, 670 Albany St., Room 510, Boston, MA 02118, USA. nrahimi@bu.edu

Abstract

A strict physiological balance between endogenous proangiogenic and antiangiogenic factors controls endothelial cell functions, such that endothelial cell growth is normally restrained. However, in pathologic angiogenesis, a shift occurs in the balance of regulators, favoring endothelial growth. Much of the control of angiogenic events is instigated through hypoxia-induced VEGF expression. The ubiquitin-proteasome system (UPS) plays a central role in fine-tuning the functions of core proangiogenic proteins, including VEGF, VEGFR-2, angiogenic signaling proteins (e.g., the PLCγ1 and PI3 kinase/AKT pathways), and other non-VEGF angiogenic pathways. The emerging mechanisms by which ubiquitin modification of angiogenic proteins control angiogenesis involve both proteolytic and nonproteolytic functions. Here, I review recent advances that link the UPS to regulation of angiogenesis and highlight the potential therapeutic value of the UPS in angiogenesis-associated diseases.

PMID:
22357635
PMCID:
PMC3297735
DOI:
10.1158/1535-7163.MCT-11-0555
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center